Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Inclusion Criteria: * Age greater than/equal to 18 years old * ECOG Performance Status of 0 - 1 * Life expectancy of at least 12 weeks * Patients with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy or have no standard therapy available * LVEF (left ventricular ejection fraction) \> or = to the lower limit of normal for the institution * Radiographically or clinically evaluable tumor * Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to start of first dose: * Hemoglobin \> 9.0 g/dL * Absolute neutrophil count (ANC) \> or = 1500/mm3 * Platelet count \> or = 100,000 /mm3 * Total bilirubin \< or = 1.5 times the upper limit of normal * ALT (alanine aminotransferase) and AST (aspartate aminotransferase) \< or = 2.5 x upper limit of normal (\< or = 5 x upper limit of normal for patients with liver involvement) * PT-INR (prothrombin-international normalized ratio) and PTT (partial thromboplastin time) \< or = 1.5 times the upper limit of normal * Serum creatinine \< or = 1.5 times the upper limit of normal Exclusion Criteria: * History of impaired cardiac function or clinically significant cardiac disease (i.e. congestive heart failure (CHF) NYHA (New York Heart Association) Class III or IV); active coronary artery disease, myocardial infarction within 6 months of study entry; new onset or unstable angina within 3 months of study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy * Type 1 or type 2 diabetes mellitus or fasting glucose \> 125 mg/dL or HgBA1c \> or = 7.0 * Use of systemic corticosteroids within 2 weeks of study entry * History of retinal vein occlusion * Known glucose-6-phosphate dehydrogenase (G6PD) deficiency * Active clinically serious infection * Uncontrolled hypertension * Positive for HIV, or chronic Hepatitis B or C * Subjects undergoing renal dialysis * Known bleeding diathesis * Ongoing substance abuse * Pregnant or breast-feeding women